This clinical trial is focused on studying a type of blood cancer called Chronic Myelogenous Leukemia in chronic phase (CML-CP). The study is testing a treatment using a medication called Asciminib, which is taken as a film-coated tablet. Another form of the medication, known as Asciminib Hydrochloride, is also being used. Both forms of the medication are taken orally, meaning they are swallowed like a pill.

The purpose of the study is to see how well patients with CML-CP respond to Asciminib after they have already been treated with at least two other medications called tyrosine kinase inhibitors (TKIs). These TKIs include drugs like imatinib, nilotinib, dasatinib, bosutinib, radotinib, or ponatinib. The study will look at how many patients achieve a specific type of response called a molecular response at different times, such as at 48 weeks. The study will also monitor the safety of the treatment by checking for any side effects and changes in health markers.

Participants in the study will take the medication for a period of up to 144 weeks. During this time, they will have regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to provide more information on how well Asciminib works for patients with CML-CP who have not had success with other treatments.